Artist's Balancing Act Inspires New York's Hope Murals Project

Article

New York artist and GIST survivor, Ellen Mayer, painted "Balancing Act" to describe how she felt about her cancer experience. The artwork was later selected as one of 10 pieces to be publicly painted for The Hope Murals Project.

New York artist and gastrointestinal stromal tumors survivor, Ellen Mayer, painted "Balancing Act" in 2010 to help describe how she felt about her cancer experience and survivorship, including the constant need to balance emotions that come with it.

"I felt like I was constantly balancing in my head: Is it going to come back, is it not going to come back? That’s what this represents," she says. "All these little people represent life, and everybody in life, whether it’s cancer or anything else you’re going through, there is a point where you have to say 'OK, this is what it is and this is how I’m going to get back to balance.'"

After submitting the piece in 2010 for the Lilly Oncology on Canvas art competition, the organizers called Mayer this year to let her know that her "Balancing Act" was selected to be a part of the 10th anniversary of the competition. Mayer's original piece was made into nine large interlocking pieces, which were painted individually by the public on Oct. 23 in New York's Grand Central Terminal as part of The Hope Murals Project.

[Oncology on Canvas and The Hope Murals Project Reaches New York City]

The Hope Murals Project allows anyone who has been impacted by cancer, including patients, survivors and caregivers, to help paint a series of 10 murals around the country.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE